Membranous nephropathy (MN) is the most common cause of glomerulopathy after hematopoietic cell transplantation (HCT). 1 The vast majority of MN occur after allogeneic HCT as a late complication in the setting of graft versus host disease (GVHD). 1 Immune suppression is typically reinitiated in this context, and MN specific therapies often include a combination of steroids, calcineurin inhibitors, mycophenolate mofetil, cyclophosphamide, and/or rituximab. Although remission frequently occurs upon re-initiation of immunosuppression, approximately 20% of patients will fail to respond and may progress to end stage renal disease. 2 Here we report the rapid remission of a treatment-resistant patient with daratumumab.